2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Serina Therapeutics entered into a Common Stock Purchase Agreement and a Registration Rights Agreement with Roth Principal Investments, both dated August 21, 2026. The company can choose, at its sole discretion, to sell up to $25 million of newly issued common stock over up to 36 months, so the deal gives it a funding option while adding potential dilution at prices set below market.
Agreement dated August 21, 2026 allows the company to sell up to $25 million of newly issued common stock to Roth Principal Investments, at the company's option and with no obligation to sell.
Purchases are priced at a discount to volume weighted average price: 7% before cumulative sales reach $12.5 million and 3% after, for market open and intraday purchases.
Under NYSE American rules, issuance is capped at 5,077,554 shares, equal to 19.99% of shares outstanding before signing, unless stockholders approve more or other conditions are met.
Sales can begin only after a resale registration statement is declared effective by the SEC, and the company may direct purchases for up to 36 months from that Commencement Date.
Biomerica agreed on August 20, 2026 to sell 1,393,705 common shares at $1.60 each to institutional and individual investors, including B. Riley Principal Capital and some directors and executive officers, for gross proceeds of about $2.23 million; the deal closed August 26, 2026. The filing also gives B. Riley purchasers a board designation right while they hold at least 10% of voting power, and requires registration of the resale of the shares, with liquidated damages if deadlines are missed.
1,393,705 shares sold at $1.60 per share, about $2.23 million gross proceeds
Closing occurred August 26, 2026; agreement dated August 20, 2026
B. Riley purchasers may designate one board representative while holding at least 10% of voting power
Directors and certain officers face 180-day lock-up; company must file resale registration within 30 days of closing
On August 21, 2026, Universal Electronics entered into a Third Amended and Restated Credit Agreement with U.S. Bank as administrative agent, which restates its October 27, 2017 credit agreement. The filing says the changes revise borrowing base definitions and the fixed charge coverage and cash flow leverage ratio covenants, while other terms remain substantially the same, so the effect on shareholders depends on the full exhibit, which the filing does not summarize further.
Agreement dated August 21, 2026, with U.S. Bank National Association as administrative agent
Amends and restates the Second Amended and Restated Credit Agreement dated October 27, 2017
Revises borrowing base definitions, consolidated fixed charge coverage ratio covenant and consolidated cash flow leverage ratio covenant
Full text filed as Exhibit 10.1; schedules omitted under Item 601(a)(5) of Regulation S-K
Sky Harbour Group Corporation closed a registered direct offering of 1,000,000 Class A common shares to M-COR Capital LLC at $10.00 per share on August 26, 2026, bringing in $10.0 million in gross proceeds before offering expenses. The company said it intends to use the net proceeds for general corporate purposes, and the sale was made under an existing shelf registration statement.
Shares sold: 1,000,000 Class A common shares at $10.00 per share to M-COR Capital LLC
Gross proceeds: $10.0 million before offering-related expenses, closed August 26, 2026
Use of proceeds: general corporate purposes
Offering made under Form S-3 shelf (File No. 333-278275), effective April 10, 2024; Morrison & Foerster opinion filed as Exhibit 5.1
Northern Oil and Gas, Inc. (NOG) issued $500 million in aggregate principal amount of 7.500% Senior Notes due September 1, 2034, under an indenture with Wilmington Trust, National Association, as trustee. The company can redeem up to 40% of the notes before September 1, 2029 using equity offering proceeds, and holders can require repurchase at 101% of principal upon a change of control.
Notes: $500 million, 7.500% coupon, maturing September 1, 2034; interest paid semi-annually from March 1, 2027
Early redemption before September 1, 2029 at 107.500% of principal from equity offering proceeds, or at 100% plus a make-whole premium
Redemption prices from September 1, 2029: 103.750% in 2029, 101.875% in 2030, 100.000% in 2031 and after
Indenture covenants limit debt, dividends, asset sales and mergers; the covenants end if the notes reach investment grade
LeonaBio said it has enrolled the 500th subject in its Phase 3 ELAINE-3 trial of lasofoxifene with abemaciclib in ESR1-mutated metastatic breast cancer. The filing also sets the start of the exercise window for 23,031,494 Series A Common Warrants at $6.35 per share, which could bring about $146.2 million in cash if fully exercised, and states that the enrollment announcement triggers that window.
500th subject enrolled in the ELAINE-3 Trial (NCT05696626), announced August 26, 2026
23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, issued in connection with the December 2025 Private Placement
Warrants become exercisable after the latest of June 30, 2026, this announcement, and FDA action on Eli Lilly's imlunestrant with abemaciclib, and no later than October 31, 2026
Full exercise would provide approximately $146.2 million; warrants expire no later than November 30, 2026
Cerence Inc. said on August 25, 2026, it agreed in privately negotiated deals to buy back $10 million of principal of its 1.50% Convertible Senior Notes due 2028 from certain holders. The repurchase price is 92.75% of principal plus accrued and unpaid interest, and the company plans to cancel the repurchased notes, which reduces its outstanding convertible debt by that amount.
Repurchase size: $10 million aggregate principal amount of the 1.50% Convertible Senior Notes due 2028
Cash repurchase price: 92.75% of principal amount, plus accrued and unpaid interest to the settlement date
Agreements entered into August 25, 2026; the company intends to cancel the repurchased notes
Following the August 19, 2026 closing of the Cox transaction, Cox entities became guarantors of and granted liens on assets securing Charter's debt, as well as several Cox note indentures. Under the filing, secured notes across the combined Charter and Cox capital structure now share the same collateral and obligors on a pari passu basis, which changes the security package behind existing debt rather than adding new borrowing.
On August 19, 2026, Charter completed the Transaction with Cox Enterprises, acquiring Cox's commercial fiber and managed IT and cloud services businesses.
On August 24, 2026, Cox entities became guarantors and granted liens under the Charter Credit Agreement with Bank of America, N.A. as administrative agent.
Supplemental indentures dated August 24, 2026 add guarantors to the CCO, Cox, TWC and TWCE indentures, with The Bank of New York Mellon as trustee.
The filing does not state a new principal amount of debt or a dollar figure for the guarantees.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.